About this event

  • Date and time Mon 1 Feb 2021 from 12:40pm to 5:00pm
  • Location Online
  • Organised by Vascular, Lipid and Metabolic Medicine Section

This webinar will provide an update on pharmacotherapy treatments that have recently become available, or are in late-stage development for the prevention and treatment of cardiovascular disease. The assessment of cardiovascular risk and optimal application of these therapies will be discussed as well.

The updates will be given by highly respected clinical researchers and thought leaders who are recognised as experts in their fields.

The online lectures will be clinically focused with the aim of educating healthcare professionals about these new therapies in the prevention and treatment of cardiovascular disease.

Topics to be covered:

  • New pharmacotherapy treatments for the prevention and treatment of cardiovascular disease
  • The use of new pharmacotherapy treatments in the context of current treatment strategies and where they will fit into existing clinical guidelines
  • Improve matching of therapy to individual cardiovascular risk profiles according to the principles of precision medicine

Join in the conversation online using #RSMLive
Follow us on Twitter: @RoySocMed

We would like to thank our sponsors Daiichi Sankyo and Sanofi for their support of this webinar.

Please note that the scientific programme and content has not been influenced in any way by sponsors.

Key speakers

Professor Kausik Ray

Professor of Public Health, Imperial College London

Speaker's biography

Professor Kausik Ray is Professor of Public Health, Consultant Cardiologist, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials in the School of Public Health, Imperial College London, and President of the European Atherosclerosis Society (EAS).


Listed in Clarivate Analytics’ list of the top 1% Highly Cited Researchers in medicine globally in 2018, 2019 and 2020, he has an H index of 84, an i10 of 216 and around 90,000 citations. Key contributions have influenced European and American guidelines, his work on statins and diabetes risk has led to a global label change for statins by the FDA and EMEA.


He is involved in 8 trials in lipids and diabetes and is PI for ORION 1, 3, 11 and BETonMACE. He leads the EAS FH Studies Collaboration, the first global registry of FH with 70 countries and 62,000 cases, and is Senior PI for the TOGETHER study looking at cardiometabolic risk in vascular health checks in 250,000 people. His research focuses on preventing coronary disease, specifically lipids, diabetes, biomarkers, and risk prediction.

Professor Paul Durrington

Professor of Medicine, University of Manchester

Speaker's biography

Professor Paul Durrington retired from his substantive post as Professor of Medicine at the University of Manchester in 2009 and retired as Consultant Physician at Manchester Royal Infirmary, in 2012. He continues to work in the Cardiovascular Research Group of the University of Manchester as Honorary Professor of Medicine. He graduated in physiology and medicine at the University of Bristol and trained in general (internal) medicine, diabetes mellitus and metabolic disorders. From 1979-80, he worked at the University of California, San Diego, as a travelling fellow of the British Heart Foundation and American Heart Association.


His research interests centre on disorders of lipoprotein metabolism, atherogenic modification of lipoproteins, insulin resistance and diabetes and the translation of clinical trial evidence into practice. In 2001 he was elected to the Fellowship of the Academy of Medical Sciences for his work on diabetic dyslipidaemia and on HDL metabolism.


He was Chairman of the British Hyperlipidaemia Association (1992-1995), a member of the British Heart Foundation Project Grants Committee (1997-2000), Director of Research and Development at the Central Manchester Healthcare Trust (1997-2001) and from 2008 to2012 he led the Greater Manchester Vascular Research Network. He was a member of the European Cardiac Society Task Force on Dyslipidaemia (2009-2015) and is from time to time a consultant to the National Institute of Health and Care Excellence (NICE) and an editor of Current Opinion in Lipidology.


In 2010 he gave the Myant Lecture to HEART UK. Currently, he chairs the steering committee of the National Institute of Health Research funded HealthTechnology Assessment Project:15/134/02 - evaluating alternative protocols for identifying and managing patients with familial hypercholesterolaemia: cost-effectiveness analysis with a qualitative study.


He is author of over 400 original papers and other publications including Hyperlipidaemia: Diagnosis and Management 3rd Edition (2007, London: Hodder Arnold).

Dr Jaimini Cegla

Consultant in Metabolic Medicine, Imperial College Healthcare NHS Trust

Speaker's biography

Dr Jaimini Cegla has a specialist interest in lipidology and cardiovascular risk and splits her time between clinical, laboratory and academic research roles. In her clinical role she looks after the Hammersmith Hospital Lipid Service, a one-stop centre for the genetic diagnosis and management of lipid disorders.


Her current research focuses on cardiovascular risk including clinical trials of novel therapeutic agents.


Dr Cegla is a member of the Medical, Scientific and Research Committee of HEART UK, the cholesterol charity. She also sits on the National Cardiovascular Disease Prevention System Leadership Forum, the advisory group of Public Health England for a strategy on cardiovascular disease prevention.

Gary Lopaschuk

Dr Gary D. Lopaschuk

Distinguished University Professor of Pediatrics at the University of Alberta, Edmonton, Canada

Speaker's biography

Dr Gary Lopaschuk's research focuses on the regulation of fatty acid oxidation in the heart, and the mechanism by which high rates of fatty acid oxidation contribute to heart disease and heart failure. He is also examining how alterations in fatty acid metabolism contribute to cardiovascular disease in the diabetic. At a molecular level he has characterized a number of key enzymes important in the regulation of cardiac fatty acid oxidation. He is also developing a number of therapeutic strategies that involve optimizing energy metabolism in the heart that can be used to prevent the development of heart disease, and that can also be used to treat heart failure.


Dr Lopaschuk's research has resulted in the publication of over 440 original research articles, and he has been recognized by awards such as the Canadian Cardiovascular Research Achievement Award, the International Academy of Cardiovascular Sciences Research Achievement Award, and a Fellowship of the Royal Society of Canada.


Dr Lopaschuk serves on a number of journal editorial boards, including Circulation Research, Journal of Clinical Investigation, American Journal of Physiology, Cardiovascular Research, Journal of Molecular and Cellular Cardiology, Canadian Journal of Physiology and Pharmacology, Heart and Metabolism, and Cardiovascular Drugs and Therapy.




View the programme

Welcome and introduction

Professor Andrew Krentz, University of Reading and King’s College London, President-Elect, Vascular, Lipids & Metabolic Medicine section, Royal Society of Medicine

Evolution of cardiovascular risk management: a clinical perspective

Dr Alan Rees, University Hospital of Wales, Past-President, Vascular, Lipid and Metabolic Medicine Section and Trustee and Past-Chair, HEART UK

LDL-cholesterol lowering drugs: Recent advances and novel therapies
Professor Kausik Ray, Professor of Public Heath, Consultant Cardiologist, Deputy Director, Imperial Clinical Trials Unit, Head of Commercial Trials, School of Public Health, Imperial College London and President, European Atherosclerosis Society
Triglycerides – A re-emerging target in atherosclerotic cardiovascular disease prevention and microvascular complications of obesity and diabetes

Dr Handrean Soran, University of Manchester

Lipoprotein(a): Emerging from the shadows?

Dr Jai Cegla, Consultant in Metabolic Medicine, Imperial College Healthcare NHS Trust

Panel discussion
Comfort break and Sponsor Presentation

What is the evidence for DOACS in anticoagulation management of NVAF patients?

Video presentation given by Khalid Khan, Consultant Cardiologist, Betsi Cadwaladr University Health Board. This session is optional and is sponsored by Daiichi Sankyo.

What should be the goal of cholesterol-lowering treatment? A quantitative evaluation

Professor Paul Durrington, Professor of Medicine, University of Manchester

Managing atherosclerotic cardiovascular disease: How close are we to precision risk assessment and individualizing treatment?

Professor Brian Ference, University of Cambridge

Myocardial metabolism: New cardioprotective drugs

Professor Gary Lobaschuk, Professor of Pediatrics, University of Alberta, Edmonton

Panel discussion
Close of webinar




Disclaimer: All views expressed in this webinar are of the speakers themselves and not of the RSM.

Special rates for difficult times 
The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s ​weekly COVID-19 Series ​webinars remain free of charge, while there will be small charges to register for other online education. These fees will enable the RSM to continue its programme of activities and will apply during the course of the pandemic.

Registration for this webinar will close 2 hours prior to the start time. You will receive the webinar link 2 hours before the meeting. Late registrations will not be accepted.

This webinar will be not be recorded and therefore will not be available to delegates after the live broadcast. 

Man searching computer

Join the RSM and get free access to digital learning resources

The RSM has an extensive digital learning and online e-resources platform. As a member you'll enjoy free access to a wealth of online  resources, including 5,000 subscription and open access e-journals, 2,000 e-books and 5 key medical databases, to support your clinical decision-making and research.

Become a member